PCM
BIOA

Prelude Capital Management’s BioAge Labs BIOA Stock Holding History

Prelude Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,193
Closed -$219K – 1614
2025
Q3 		$219K Sell
37,193
-15,946
-30% -$74.7K 0.02% 896
2025
Q2 		$219K Buy
53,139
+35,639
+204% +$144K 0.02% 771
2025
Q1 		$65.8K Sell
17,500
-2,300
-12% -$10.6K 0.01% 1076
2024
Q4 		$115K Buy
+19,800
New +$341K 0.01% 1081

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Prelude Capital Management's BIOA Position: Q4 2025 in Review

Prelude Capital Management sold out of BioAge Labs (BIOA) in Q4 2025, closing a stake of 37,193 shares — an estimated $219K sold.

Prelude Capital Management first reported a position in BIOA in Q4 2024 and held it in 4 quarters. The position peaked at $219K in Q2 2025. 114 funds tracked by Wall St. Rank hold BIOA as of Q4 2025.

  • Prelude Capital Management reported no remaining BioAge Labs position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 37,193 BioAge Labs shares in Q4 2025, an estimated $219K.
  • Prelude Capital Management first reported a position in BioAge Labs in Q4 2024 and held it in 4 quarters.
  • Prelude Capital Management's BioAge Labs position peaked at $219K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held BioAge Labs as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.